AORTArtivion Inc. Common Stock

Shares of medical device company Artivion (NYSE:AORT) jumped 2.5% in the afternoon session after Canaccord Genuity raised its price target on the stock to $40 from $39 while maintaining a Buy rating.

Artivion’s second quarter results were well received by the market, with performance driven by accelerating growth in its stent graft and On-X heart valve portfolios. Management credited strong On-X adoption, improved stent graft set sales, and a return to growth across international markets as key drivers behind the positive momentum. CEO Pat Mackin highlighted the recent FDA approval of the AMDS hybrid prosthesis and the acquisition of Endospan’s NEXUS system as important milestones, noting, “

Revenue grew 9% as heart valve and stent graft products drove results.

Medical device company Artivion (NYSE:AORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.3% year on year to $125.8 million. The company expects the full year’s revenue to be around $488 million, close to analysts’ estimates. Its non-GAAP profit of $0.13 per share was 34.5% above analysts’ consensus estimates.

Artivion (NYSE:AORT) reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined rou

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]

Artivion Inc (AORT) reports 9% constant currency revenue growth in Q2 2026, fueled by strong stent graft and ONIX performance, while navigating integration costs and maintaining full-year guidance.

Artivion (AORT) delivered earnings and revenue surprises of 0.00% and +4.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical device company Artivion (NYSE:AORT) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.3% year on year to $125.8 million. The company expects the full year’s revenue to be around $488 million, close to analysts’ estimates. Its non-GAAP profit of $0.13 per share was 34.5% above analysts’ consensus estimates.

Steris (STE) delivered earnings and revenue surprises of +1.97% and -0.83%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Artivion (AORT) is back on investors’ radar after new focus on its business model and capital efficiency, highlighting the company’s smaller revenue base, limited free cash flow, and ongoing return on capital challenges. See our latest analysis for Artivion. Recent price action has been mixed for Artivion, with a 1 month share price return of 14.6% coming after a 90 day share price decline of 20.9%, while the 3 year total shareholder return of 63.6% contrasts with weaker results over 1 year...

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 17% over the past six months while the S&P 500 was up 8.3%.

Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. U.S. equities experienced a strong recovery in Q2 2026, with the S&P 500 Index gaining 15.2%, marking its best quarter since 2020. A ceasefire between the United States […]

Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +12.90% and +3.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Artivion’s stock price has taken a beating over the past six months, shedding 43.8% of its value and falling to $24.10 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.